Skip to main content
OpenTrials
Completed

NCT Number: NCT04140292

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

This study is open to individuals with Actinic Keratoses (skin lesions that have the potential to turn into skin cancer), who are receiving photodynamic therapy (PDT) as part of their clinical care. The purpose of this study is to test and demonstrate that vitamin D pre-treatment can enhance PDT efficacy in the treatment of Actinic Keratoses.

Participants will be asked to take vitamin D supplements prior to their standard of care PDT treatment.

Participation in the research will last about 3-4 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Actinic Keratosis Keratosis Keratosis, Actinic Neoplasms Precancerous Conditions Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

Cleveland, Ohio, 44195, United States

About this study

The primary objective of this study is to determine whether acute supplementation (neoadjuvant Vitamin D3), adjusted according to baseline Vitamin D status, can improve the clinical PDT response relative to participants receiving PDT alone

The secondary objective of this study is to determine whether gene polymorphisms in VDR and CYP27B1 are predictive for the degree of responsiveness to Vitamin D as a neoadjuvant for PDT.

This study is a non-randomized interventional trial, in which the study group will be compared to a baseline cohort of patients from a previous study who received the same regimen of PDT, but without any Vit D. It is anticipated that 30 participants will be involved in this study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Actinic keratoses in sufficient numbers (>10) to warrant PDT therapy in the clinic
  • Able to understand and willing to sign a written informed consent document
  • Female subjects must not become pregnant during the study:
  • The effects of 5-aminolevulinic acid (LevulanTM) on the human fetus are unknown. For this reason, women of child-bearing potential must agree to use contraception (double barrier method of birth control or abstinence) prior to study entry, and throughout study participation. Should a woman become pregnant or suspect that she is pregnant while she is participating in this study, she should inform the treating physician immediately.

Exclusion criteria

  • Pregnant or nursing.
  • At risk for hypercalcemia (renal disease, sarcoidosis, etc.)
  • Using topical retinoids, since these can exacerbate the post-PDT erythema reaction.
  • Using any topical treatment on their AKs; must stop at least one month prior.
  • Currently undergoing treatment for other cancers with medical or radiation therapy.
  • Patients with a known hypersensitivity to 5-aminolevulinic acid or any component of the study material.
  • Patients with history of a photosensitivity disease, such as porphyria cutanea tarda.
  • Currently participating in another clinical trial.

Treatment and study plan

Photodynamic therapy (PDT)

Drug

PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells

Noninvasive fluorescence dosimetry may be performed on up to 6 lesions. Levulan Kerastick will be applied to each lesion and left to incubate for 30 minutes. Blue light (Blu-U device, 20 J/cm2, 33 minutes) will be administered.

Vitamin D3

Drug

D3 pills (10,000 IU each) to be taken daily at home, beginning at either day -5 or day -14, as per their assignment

Participants will receive a 5-day or 14-day supplementation of Vitamin D10,000 IU depending on their baseline Vitamin D 25 Hydroxy result

Primary outcomes

  1. Clinical PDT Response as Measured by Percent Change in AK Lesions From Baseline to 3 Months

    Time frame: 3 months after treatment

    Clinical PDT response as measured by the percent change of AK lesions 3 months after treatment

    Baseline vitamin D (calcidiol) level will be taken for each patient.

Secondary outcomes

  1. Correlation Between Vitamin D Receptor (VDR) Polymorphisms and Percent Reduction in AK

    Time frame: 3 months after treatment

    Whether gene polymorphisms in VDR and CYP27B1 are predictive for the degree of responsiveness (as measured by percent reduction in AK) to Vitamin D as a neoadjuvant for PDT.

  2. Number of Participants Reporting 1 or Higher on the Pain Scale

    Time frame: During treatment (at the 5 min mark), and again immediately afterwards.

    Pain scale recorded on a 0-to-10 visual/analog scale, with higher scores mean more pain; 0 is no pain, 10 is "the worst pain imaginable". Number of participants receiving treatment that reported a pain level greater than 1.

  3. Tolerability as Measured by Participants' Symptom Score Sheets

    Time frame: 1 week after treatment

    Participants are asked to recall the symptoms they experienced during the week following PDT. The study physician asks them whether they had experienced each of the following 13 symptoms (YES/NO), and positive (YES) answers were summed to create a Side Effects Score (SES). The maximum and minimum possible values are 13 and 0 respectively, with a higher score correlating to poorer participant outcomes.

    The 13 possible side effects were: pain, erythema, scabbing, blistering, erosions, edema, warmth, exfoliation, discharge, hemorrhage, tightness, hyperpigmentation, hypopigmentation.

  4. Accumulation of Protoporphyrin IX (PpIX) Within AK

    Time frame: 3 months after treatment

    Accumulation of protoporphyrin IX (PpIX) within AK

    PpIX accumulation in areas of both actinic damage and normal skin will be measured with a fluorescence dosimeter. The level of calcidiol, a clinically accepted marker of vitamin D status, will be measured in each patient to see if supplementation with 10,000 IU of Vitamin D increase the accumulation

Sponsors and collaborators

Lead sponsor

Case Comprehensive Cancer Center

Other

Registry information

Important dates

Study start
2020
Primary completion
2020
Study completion
2021
First posted
Oct 25, 2019
Registry last updated
Jun 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.